Last reviewed · How we verify

NCT07279220

Safety and Effectiveness of the Vascular Closure Device for Femoral Artery Hemostasis in Patients of Femoral Artery Puncture

Not yet recruiting NA Last updated 12 December 2025
What this trial tests

NA trial testing Vascular Closure Device Manufactured by Shanghai Bomaian Medical Technology Co., Ltd. in Femoral Artery Puncture in 238 participants. Not yet recruiting.

Timeline
29 December 2025
Primary endpoint
2 March 2026
15 May 2026

Quick facts

Lead sponsorShanghai Bomaian Medical Technology Co., Ltd
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment238
Start date29 December 2025
Primary completion2 March 2026
Estimated completion15 May 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai Bomaian Medical Technology Co., Ltd

Who can join

Adults 18 to 80, any sex, with Femoral Artery Puncture or Vascular Closure Device. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to verify the safety and effectiveness of the Vascular Closure Device manufactured by Shanghai Bomaian Medical Technology Co., Ltd. for femoral artery hemostasis in patients of femoral artery puncture.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai Bomaian Medical Technology Co., Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07279220.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing